These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19239363)

  • 1. Raltegravir and etravirine are active against HIV type 1 group O.
    Briz V; Garrido C; Poveda E; Morello J; Barreiro P; de Mendoza C; Soriano V
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):225-7. PubMed ID: 19239363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
    Do VT; Higginson RT; Fulco PP
    Am J Health Syst Pharm; 2011 Nov; 68(21):2049-54. PubMed ID: 22011983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 4. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
    Wirden M; Simon A; Schneider L; Tubiana R; Malet I; Ait-Mohand H; Peytavin G; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2009 Nov; 64(5):1087-90. PubMed ID: 19717396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.
    Di Biagio A; Bruzzone B; Rosso R; Viganò O; Icardi G; Viscoli C; Rusconi S
    AIDS Patient Care STDS; 2008 May; 22(5):355-7. PubMed ID: 18373415
    [No Abstract]   [Full Text] [Related]  

  • 7. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
    Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

  • 9. Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.
    Westin MR; Biscione F; Ribeiro KM; Greco DB; Tupinambás U
    AIDS Res Hum Retroviruses; 2014 Feb; 30(2):113-7. PubMed ID: 23875625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
    Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
    J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.
    Flandre P; Marcelin AG; Calvez V;
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):448-454. PubMed ID: 28653971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
    Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
    Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
    Tambuyzer L; Thys K; Hoogstoel A; Nijs S; Tomaka F; Opsomer M; De Meyer S; Vingerhoets J
    Antivir Ther; 2016; 21(4):317-27. PubMed ID: 26566161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
    Boyd SD; Maldarelli F; Sereti I; Ouedraogo GL; Rehm CA; Boltz V; Shoemaker D; Pau AK
    Antivir Ther; 2011; 16(2):257-61. PubMed ID: 21447876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of raltegravir resistance during therapy.
    Sichtig N; Sierra S; Kaiser R; Däumer M; Reuter S; Schülter E; Altmann A; Fätkenheuer G; Dittmer U; Pfister H; Esser S
    J Antimicrob Chemother; 2009 Jul; 64(1):25-32. PubMed ID: 19447792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
    Charpentier C; Fagard C; Colin C; Katlama C; Molina JM; Jacomet C; Visseaux B; Taburet AM; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    PLoS One; 2013; 8(1):e53621. PubMed ID: 23349724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.
    Hill A; Grossman H; Cohen C; Nadler J; Peeters M
    HIV Clin Trials; 2007; 8(2):68-76. PubMed ID: 17507322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.